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Serum insulin-like growth factor-1 (IGF-1) is a sensitive marker of growth hormone (GH) activity. The levels of IGF-1 vary widely,
peaking during puberty and declining with advancing age. During adolescence, serum IGF-1 levels tend to correlate better with
pubertal stage rather than chronological age. Here we discuss two cases of delayed puberty, both in their 20s, who presented with
high serum IGF-1 but no clinical or biochemical evidence of hypersomatotropism as conﬁrmed by appropriate GH response to
an oral glucose challenge. Both individuals achieved full pubertal status with testosterone replacement therapy and their serum
IGF-1 levels settled into normal age-speciﬁc range. We suggest that in chronologically adult individuals with delayed puberty,
serum IGF-1 should not be interpreted on the basis of age-speciﬁc normal values but rather on their pubertal status. Furthermore,
in the absence of another cause of elevated IGF-1, the expectation is that IGF-1 levels will decline towards age-normative ranges
following androgen replacement therapy.
1.Introduction
The measurement of serum insulin-like growth factor-1
(IGF-1) is a useful screening test for acromegaly [1]. The
normal reference range for IGF-1 varies widely, peaking
during puberty and declining with advancing age [2]. With
the onset of puberty, the release of growth hormone (GH)
is stimulated through sex steroids with estrogen being the
main stimulator of GH release both in males and females
[3].Althoughinmalestestosteronealsostimulatestherelease
of GH, the majority of the GH eﬀect still occurs through
aromatization of testosterone to estrogen [4]. Once puberty
has been completed, the levels of serum IGF-1 drop by ﬁfty
percent during early adulthood and then continue to decline
throughout adult life [2]. Therefore, serum IGF-1 levels are
interpreted against age and gender-speciﬁc reference ranges.
Here we describe 2 cases of delayed puberty who presented
with elevated IGF-1 levels that normalized with androgen
replacement therapy.
Case 1. A 21-year-old male university student was referred
to our centre for bilateral gynecomastia and delayed puberty.
He reported minimal pubic hair development at the age
of 16, absent sense of smell, and inability to ejaculate. He
had undergone varicocele surgery at age 15. On clinical
examination, he was 194cm tall with a body mass index
(BMI) of 22Kg/m2,a n dh a da na r ms p a no f2 0 2 c m .H i s
visual ﬁelds were normal, and there were no midline defects.
The testicular volumes were 5 and 8mLs for right and
left testes, respectively, with an infantile phallus, graded as
Tanner stage 2. Serum total testosterone was low on two
separate occasions at 1.0 and 3.4nmol/L (normal range
for adult: 8.4–28.7 and for Tanner stage 2: 0.6–5.3), and
serum follicle stimulating hormone (FSH) and luteinizing
hormone (LH) levels were 0.4 and 0.3IU/L, respectively,
(normal ranges: 1.4–18.1IU/L and 1.5–9.3IU/L, resp.) thus
conﬁrming secondary hypogonadism. The remaining pitu-
itary function tests, including serum thyroid stimulating
hormone (TSH), free T4, morning cortisol, and prolactin,2 International Journal of Endocrinology
were normal. His serum IGF-1 was elevated to 485 and
675ug/L on two separate occasions (normal range for males
age 21–25 years: 116–358ug/L. (All IGF-1 estimations were
performed using Siemens Immulite 2500 chemiluminescent
assay (Siemens, IL, USA). The normal reference ranges are
stratiﬁed by 1-year intervals until age 20 and then 5-year
intervalsuntilage85.)The5-houroralglucosetolerancetest
showed appropriate suppression of growth hormone to less
than 1ug/L, and MRI did not reveal any abnormality in the
hypothalamic-pituitary region. He was clinically diagnosed
as having Kallmann’s syndrome and started on testosterone
replacement therapy in the form of testosterone enanthate
injections. Three years later, he had normal serum total
testosterone and he had achieved Tanner stage 5 pubertal
development. His BMI remained unchanged and his IGF-1
normalized at 312ug/L.
Case 2. A 22-year-old male presented with secondary
hypogonadism as a result of investigation by his general
practitioner for loss of libido, erectile dysfunction, and
fatigue. His history was unremarkable for any cause of
hypogonadism. On examination, he was 170cm tall and
weighed 113kg with a BMI of 39.1kg/m2. He was Tanner
stage4forbothpubichairandgenitaldevelopment,with12–
15mL testes bilaterally. Initial biochemical testing showed a
total testosterone of 6.1nmol/L (normal range for adult: 8.4–
28.7 and for Tanner stage 4: 7.0–21.7) with an undetectable
LH and FSH. Repeat testing 3 months later showed a total
testosterone of 3.2nmol/L, with an FSH of 0.6IU/L and
LH of 0.1IU/L. Serum morning cortisol, TSH, free T4, and
prolactin levels were normal; however, serum IGF-1 was
above reference range at 405ug/L (normal range for males
age 21–25 years:116-358ug/L. (All IGF-1 estimations were
performed using Siemens Immulite 2500 chemiluminescent
assay (Siemens, IL, USA). The normal reference ranges
are stratiﬁed by 1-year intervals until age 20 and then
5-year intervals until age 85.) The oral glucose tolerance
testing was normal, demonstrating GH suppression to less
than 1ug/L. MRI of the sella revealed a normal pituitary
with no anatomical abnormalities in the hypothalamic-
pituitary region. In view of the biochemical evidence of
hypogonadism, he was started on intramuscular testosterone
enanthate replacement therapy which normalized his serum
total testosterone. One year later, he achieved Tanner stage
5 puberty, his BMI remained unchanged, and his IGF-1
normalized to 258ug/L.
2. Discussion
The two cases presented here highlight an association
between delayed puberty due to central hypogonadism and
elevated IGF-1 levels. In both cases, these individuals did
not have clinical or biochemical evidence of hypersoma-
totropism, as conﬁrmed by an appropriate GH response to
an oral glucose challenge, and their IGF-1 levels normalized
within 12–36 months of starting androgen replacement
therapy.
Measurement of serum IGF-1 is a sensitive marker of
GH activity, and, based on recent guidelines, a low serum
IGF-1 in patients with a history of organic pituitary disease
conﬁrms growth hormone deﬁciency whereas an elevated
IGF-1 is regarded as the best single test for the diagnosis of
acromegaly [5]. The circulating IGF-1 is mostly produced in
the liver with GH being the primary regulator of serum IGF-
1 levels. In addition to GH, several other factors modulate
serum IGF-1 concentration. For instance, reduced caloric
intake and conditions associated with malnutrition such
as inﬂammatory bowel disease, renal failure, and hepatic
failure are associated with low IGF-1 levels [6, 7]. On
the contrary, serum IGF-1 levels may be elevated during
pregnancy primarily due to the highly somatogenic eﬀect
of placental GH which mostly replaces circulating pituitary
GH [8]. The association between obesity and IGF-1 is
controversial with some studies reporting high [9, 10] while
others reporting low IGF-1 levels [11]i na s s o c i a t i o nw i t h
obesity. The pubertal rise in IGF-1 levels reﬂects an increase
in GH secretion at puberty [12] and the eﬀect of gonadal
steroids which increase GH concentration by increasing
the growth hormone releasing hormone pulse amplitude
[4]. Serum IGF-1 levels are evaluated against age- and
gender-adjusted normative values. These values are low at
birth, peak during late puberty, fall to about half maximal
concentrations in the second to third decades, and continue
to decline as aging occurs [2]. During adolescence, IGF-
1 levels tend to correlate better with the Tanner stage of
puberty as opposed to chronological age, peaking quickly by
Tanner stage 3-4 in girls and Tanner stage 4 in boys [13, 14].
In our patients the normal reference ranges for serum IGF-1
based on their Tanner stages were 67–414ug/L (Case 1)a n d
187–854ug/L (Case 2). In Case 1, serum IGF-1 was higher
than both age and Tanner stage-speciﬁc ranges whereas in
Case 2 it was above the age-speciﬁc range but within the
Tanner stage-speciﬁc normal range. These two individuals
were both in their 20s and, therefore, well past the adolescent
age group. However, they had failed to achieve puberty
until appropriate androgen replacement therapy was started.
Retrospectively, the elevated IGF-1 levels in these patients
were more congruent with their Tanner stages rather than
chronological age and these levels normalized when they
receivedandrogenreplacementtherapy.Thereareconﬂicting
reportsabouttheassociationbetweensexsteroids andserum
IGF-1 levels during pubertal years. While some studies have
suggested signiﬁcant correlation between sex steroids and
I G F - 1l e v e l si nm a l ea n df e m a l ea d o l e s c e n t s[ 15, 16], others
have reported such association only in girls and not in boys
[17]. Furthermore, serum IGF-1 levels are notably elevated
inadolescentswithprecociouspubertywheretheynormalize
after suppression of sex steroids with gonadotropin-releasing
hormone therapy [18]. Interestingly some studies have also
reported that in both hypogonadotropic females and males,
and boys with constitutional delay in puberty, treatment
with respective sex steroids increases serum IGF-1 [19–21].
Previously another study of prepubertal hypopituitary boys
treated with testosterone therapy for eight days reported
no diﬀerence in the response of IGF-1 to GH challenge
[22]. Contrary to these reports, serum IGF-1 levels were
elevated in our patients in keeping with their pubertal status
and normalized with androgen replacement therapy. DespiteInternational Journal of Endocrinology 3
demonstrating a diﬀerent response of serum IGF-1 to andro-
gen replacement therapy from the previously published data,
our observation lends support to the evidence that a deﬁnite
association exists between sex steroids and serum IGF-1
levels during pubertal period. It is diﬃcult to speculate the
reason for this disparity from other published reports, but
it may be due to the underlying pathology, duration of
treatment, and the age at assessment.
As noted earlier, unlike previously reported studies our
patients were both in their 20s, an age where such individ-
uals would normally see adult endocrinology. Most adult
endocrinology clinics tend to use age-based reference values
for IGF-1; therefore, even in this age group, such a disparity
could potentially lead to diagnostic misinterpretation. These
cases indicate that in young adults with delayed puberty,
serum IGF-1 estimation should not be based on age speciﬁc
normative values but instead should be interpreted in the
context of Tanner stage. Furthermore, in the absence of
another cause of elevated IGF-1, the expectation is that IGF-
1 levels will decline towards age-normative ranges following
androgen replacement therapy.
3. Conclusion
We describe cases of two adult males with delayed puberty
secondary to hypogonadism whose IGF-1 levels were ele-
vated for their age-speciﬁc normal reference ranges. In
both cases, these values normalized once puberty with
androgen replacement therapy was achieved. Therefore,
in chronologically adult individuals with delayed puberty,
serum IGF-1 assessment should not be based on age-speciﬁc
normal values but rather on their Tanner stage of puberty.
Since most reference laboratories currently report serum
IGF-1levelsbasedsolelyonage-andgender-basednormative
values, additional availability of such reference ranges based
on pubertal stage would avoid diagnostic confusion.
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